Immuneering Corporation (IMRX) Income Statement Analysis

See more : CF Industries Holdings, Inc. (0HQU.L) Income Statement Analysis – Financial Results

Complete financial analysis of Immuneering Corporation (IMRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immuneering Corporation, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Immuneering Corporation (IMRX)

Industry: Biotechnology

Sector: Healthcare

Website: https://immuneering.com

About Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Metric	2023	2022	2021	2020	2019
Revenue	0.00	316.95K	2.08M	2.31M	1.92M
Cost of Revenue	764.14K	158.12K	1.15M	1.28M	1.22M
Gross Profit	-764.14K	158.83K	926.89K	1.03M	696.74K
Gross Profit Ratio	0.00%	50.11%	44.56%	44.61%	36.29%
Research & Development	41.40M	36.27M	26.54M	15.00M	4.28M
General & Administrative	16.76M	15.61M	8.27M	3.11M	2.71M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00
SG&A	16.76M	15.61M	8.27M	3.11M	2.71M
Other Expenses	0.00	30.05K	-127.06K	0.00	0.00
Operating Expenses	58.41M	51.90M	34.81M	18.11M	6.99M
Cost & Expenses	58.41M	52.06M	35.97M	19.39M	8.21M
Interest Income	3.61M	1.01M	169.90K	42.66K	57.66K
Interest Expense	0.00	1.01M	0.00	0.00	351.30K
Depreciation & Amortization	352.08K	796.79K	159.07K	79.31K	18.08K
EBITDA	-58.06M	-51.47M	-33.68M	-17.00M	-7.34M
EBITDA Ratio	0.00%	-16,316.29%	-1,629.17%	-733.74%	-382.35%
Operating Income	-58.41M	-51.74M	-33.89M	-17.08M	-6.29M
Operating Income Ratio	0.00%	-16,325.77%	-1,629.17%	-739.01%	-327.71%
Total Other Income/Expenses	4.94M	1.23M	42.84K	42.66K	-1.42M
Income Before Tax	-53.47M	-50.51M	-33.84M	-17.04M	-7.71M
Income Before Tax Ratio	0.00%	-15,937.29%	-1,627.11%	-737.17%	-401.59%
Income Tax Expense	0.00	-1.23M	-307.49K	-84.34K	351.30K
Net Income	-53.47M	-49.28M	-33.54M	-17.04M	-8.06M
Net Income Ratio	0.00%	-15,548.66%	-1,612.33%	-737.17%	-419.89%
EPS	-1.88	-1.87	-1.27	-0.67	-0.32
EPS Diluted	-1.88	-1.87	-1.27	-0.67	-0.32
Weighted Avg Shares Out	28.42M	26.39M	26.32M	25.51M	25.51M
Weighted Avg Shares Out (Dil)	28.42M	26.39M	26.32M	25.51M	25.51M

Why Shares of Immuneering Jumped This Week

March 24, 2023fool.com

Immuneering is a clinical-stage biopharmaceutical that focuses on oncology therapies. The company's lead therapy is in a phase 1/2a trial.

Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

March 23, 2023zacks.com

Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

March 14, 2023globenewswire.com

Demonstrates ability to identify patient populations that may benefit from IMM-1-104 treatment

Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect?

March 9, 2023zacks.com

The average of price targets set by Wall Street analysts indicates a potential upside of 210.2% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...

Immuneering Corporation (IMRX) Q4 2022 Earnings Call Transcript

March 6, 2023seekingalpha.com

Immuneering Corporation (NASDAQ:IMRX ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Laurence Watts - Investor Relations, Gilmartin Group Benjamin Zeskind - President and Chief Executive Officer Brett Hall - Chief Scientific Officer Scott Barrett...

Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates

March 6, 2023zacks.com

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 13.79% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Announces Participation in March Investor Conferences

February 28, 2023globenewswire.com

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will participate in...

Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

February 27, 2023globenewswire.com

Management to host conference call on Monday, March 6 at 4:30 p.m. ET Management to host conference call on Monday, March 6 at 4:30 p.m. ET

Immuneering To Present at Guggenheim 2023 Oncology Conference

January 31, 2023globenewswire.com

CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activating events, today announced...